Pharmafile Logo
Pharmafocus logo
Advanced Search

Shire signs strategic partnership deal with ICON

January 10, 2012
Research and Development ICON, Shire

Contract research organisation ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to be the sole global provider of …

News

BMS to buy hep C firm Inhibitex for $2.5 billion

January 9, 2012
Research and Development, Sales and Marketing BMS, Inhibitex, hep C

Bristol-Myers Squibb will acquire virology specialist Inhibitex for $2.5 billion, expanding its infectious disease portfolio. Bristol-Myers Squibb will acquire the …

News
AstraZeneca image

AstraZeneca leaks confidential information

January 9, 2012
Sales and Marketing AstraZeneca, data leak

There have been red faces at AstraZeneca after the company sent confidential information to analysts by mistake.  It was forced …

News
Novartis building

Novartis recalls products as GMP issues close OTC facility

January 9, 2012
Manufacturing and Production FDA, Novartis, OTC

Novartis has revealed that it is temporarily shutting down a manufacturing facility in Nebraska, US, and recalling four products as …

News
Risperdal image

J&J to pay $1 billion for Risperdal charges

January 9, 2012
Sales and Marketing J&J, JJ, Janssen, Risperdal

Johnson & Johnson will pay more than $1 billion in the US to resolve a civil investigation into the marketing …

News

Celgene appoints Dr David Gillen as its UK and Ireland medical director

January 9, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Celgene

Celgene has appointed former Pfizer man Dr David Gillen as its new UK and Ireland medical director. Gillen brings much …

Appointment

Hospira faces lawsuits from disgruntled investors

January 9, 2012
Manufacturing and Production Hospira, generics, manufacturing

Angry investors in US generic drugmaker Hospira have filed a class action lawsuit against the company, alleging that it misled …

News

Merck chief defends ‘bumpy’ 2011

January 6, 2012
Sales and Marketing Kenneth Frazier, Merck

Kenneth Frazier has defended his company’s ‘bumpy’ performance in 2011, and has highlighted key drugs for investors to watch. Frazier …

News
Merkel and Sarkozy

2011 Year In Review

January 6, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Europe, emerging markets, year in review

A round up of some of the key themes in pharma’s yearEUROPE IN CRISIS While the Eurozone has averted meltdown …

Feature

New requirements for the technical validations of Marketing Authorisation Applications

January 6, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

The current EU- eCTD v3.1 validation criteria came into force on 1st September 2011 for the technical validation for all …

News
Press release

GSK faces fine over Argentina clinical trial

January 6, 2012
Research and Development, Sales and Marketing Argentina, GSK, Vaccine, deaths, emerging markets

A court in Argentina says GSK should be fined for irregularities in recruitment during a trial in which children died. …

News

FDA: don’t broadcast discussion on off-label uses

January 6, 2012
Medical Communications FDA, Facebook, Twitter, off label, social media

The FDA has released long-awaited guidance for pharma firms about social media use. The FDA held a two-day public hearing …

News
lilly_entrance_web

Lilly pessimistic on 2012 performance

January 6, 2012
Sales and Marketing Eli Lilly, lilly, zyprexa

Lilly is forecasting a drop in revenue and profits for 2012, as it prepares for life without its blockbuster antipsychotic …

News
Lipitor UK video

Keep prescribing Lipitor – the generics are nearly here, says Pfizer

January 5, 2012
Medical Communications, Sales and Marketing Lipitor, NHS, Pfizer, statin prescribing

Pfizer has launched a campaign to persuade UK doctors to keep prescribing Lipitor ahead of its patent expiry in May. …

News

Biogen inks $299m deal for rare genetic disorder drug

January 5, 2012
Research and Development, Sales and Marketing Biogen, Isis Pharma

Biogen has signed a new deal with drug discovery firm Isis for its spinal muscular atrophy drug ISIS-SMNRx. Biogen will pay …

News

AstraZeneca to take Alzheimer’s drug into phase II

January 5, 2012
Research and Development Alzheimer's, AstraZeneca, Targacept

AstraZeneca is to continue the development of Targacept’s AZD1446 as a treatment for Alzheimer’s disease.AZD1446 is a selective modulator of …

News

UK to expand telehealth to three million people

January 4, 2012
Medical Communications, Sales and Marketing NHS, long term conditions, telecare, telehealth

The NHS is to expand the use of telehealth, allowing doctors to remotely monitor patients with long-term conditions.The government’s Care …

News

Orphan status for haemophilia gene therapy

January 4, 2012
Research and Development AMT, gene therapy, haemophilia

Amsterdam Molecular Therapeutics has been granted an orphan drug designation for its gene therapy for haemophilia B.The FDA’s orphan designation …

News

Missing trial data ‘threatens integrity of medicine’

January 4, 2012
Research and Development, Sales and Marketing BMJ, clincial trial data, disclosure

Missing clinical trial data can harm patients and lead to needless costs for health systems, according to new research. A …

News

Yanai steps down as Teva’s chief executive after four years at the helm

January 3, 2012
Medical Communications Teva

Shlomo Yanai is to step down as the chief executive and president of Teva, the world’s biggest generic drug makers. …

Appointment
The Gateway to Local Adoption Series

Latest content

Alto Neuroscience announces new patent for depression treatment

January 15, 2026

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

January 15, 2026

Bio-Sourcing and Zerion Pharma receive 1.3m euros in funding for joint breast cancer project

January 14, 2026

Biocartis announces breast cancer research collaboration with US Mayo Clinic

January 14, 2026

Blue Earth announces first UK patient received prostate cancer injection

January 13, 2026